04.27.26 -- March 2026 — CDMO Opportunities And Threats Report

Discover real-world AI applications in gene therapy through detailed case studies. We address critical implementation hurdles and the technical prerequisites needed for smarter manufacturing.

Navigate the shift to GMP by controlling process variability and refining design. These strategies support reliable clinical manufacturing and ensure your therapy is ready for the next stage.

Selecting the right CDMO is critical for biopharma success. The ideal partner offers end-to-end capabilities, scientific expertise, quality culture, agility, and transparent collaboration from concept to commercialization.

Improve product titers and stability in CHO cell manufacturing using data-driven vector design. This approach ensures long-term expression quality while streamlining your production workflow.

As developers begin their AAV therapy research, opting to conduct early phase studies with an experienced CDMO can help mitigate funding challenges and procure material for clinical data generation.

Optimized RNA modifications and delivery platforms offer a scalable path to potent mRNA therapeutics. Learn how dose optimization leads to safer, more efficient gene editing outcomes in vivo.

Watch how data-driven manufacturing and end-to-end supply chain orchestration can help cell therapy developers overcome manufacturing challenges, reduce costs, and scale programs more effectively.

Strengthen your viral safety strategy by applying science- and risk-based approaches to viral clearance planning, ensuring robust data, regulatory compliance, and patient protection.

Learn how off-the-shelf, GMP-grade iPSC lines with a Drug Master File (DMF) can accelerate cell therapy development, streamline regulatory approval, and reduce time and cost to clinic.

Next-gen circular DNA improves payload stability and reduces cytotoxicity. Explore how these payloads enable precise, scalable integration across various recombination and transposition systems.

Evolving regulations require proactive impurity control using trace‑level detection, solid risk assessment, advanced analytics, and ongoing monitoring to prevent compliance issues.